OM:SENZA

Stock Analysis Report

Executive Summary

SenzaGen AB, together with its subsidiary, markets, sells, and performs in vitro genomic allergen rapid detection (GARD) sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals and cosmetic ingredients in Sweden and internationally.

Snowflake

Fundamentals

Excellent balance sheet and overvalued.

Share Price & News

How has SenzaGen's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.6%

SENZA

2.3%

SE Biotechs

2.2%

SE Market


1 Year Return

-54.5%

SENZA

-16.5%

SE Biotechs

16.0%

SE Market

Return vs Industry: SENZA underperformed the Swedish Biotechs industry which returned -16.5% over the past year.

Return vs Market: SENZA underperformed the Swedish Market which returned 16% over the past year.


Shareholder returns

SENZAIndustryMarket
7 Day-0.6%2.3%2.2%
30 Day-31.4%-2.0%2.7%
90 Day-40.9%-14.6%4.2%
1 Year-54.5%-54.5%-16.1%-16.5%21.0%16.0%
3 Yearn/a29.7%19.8%34.5%14.2%
5 Yearn/a51.2%53.3%61.7%27.1%

Price Volatility Vs. Market

How volatile is SenzaGen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SenzaGen undervalued compared to its fair value and its price relative to the market?

3.76x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SENZA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SENZA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SENZA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SENZA is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SENZA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SENZA is good value based on its PB Ratio (3.8x) compared to the SE Biotechs industry average (3.7x).


Next Steps

Future Growth

How is SenzaGen forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SenzaGen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has SenzaGen performed over the past 5 years?

-37.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SENZA is unprofitable, and losses have increased over the past 5 years at a rate of -37.4% per year.

Accelerating Growth: Unable to compare SENZA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SENZA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.4%).


Return on Equity

High ROE: SENZA has a negative Return on Equity (-30.77%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SENZA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SENZA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is SenzaGen's financial position?


Financial Position Analysis

Short Term Liabilities: SENZA's short term assets (SEK47.8M) exceeds its short term liabilities (SEK4.0M)

Long Term Liabilities: SENZA's short term assets (47.8M) exceeds its long term liabilities (1.3M)


Debt to Equity History and Analysis

Debt Level: SENZA is debt free.

Reducing Debt: SENZA had no debt 5 years ago.


Balance Sheet

Inventory Level: SENZA has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if SENZA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SENZA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SENZA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -45.2% each year


Next Steps

Dividend

What is SenzaGen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SENZA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SENZA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SENZA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SENZA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SENZA's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of SenzaGen's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Axel Sjöblad (52yo)

0.3yrs

Tenure

0

Mr. Axel Sjöblad, MBA. EMBA has been Chief Executive Officer of SenzaGen AB. since June 17, 2019. Mr. Sjöblad was Managing Director of BioGaia AB from March 1, 2016 to June 30, 2018. Mr. Sjöblad serves as  ...


Management Age and Tenure

0.8yrs

Average Tenure

51yo

Average Age

Experienced Management: SENZA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

3.8yrs

Average Tenure

53.5yo

Average Age

Experienced Board: SENZA's board of directors are considered experienced (3.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Sellkr149,43805 Nov 18
3Rs Management And Consulting Aps
EntityCompany
Shares3,555
Max Pricekr42.04
Sellkr244,89529 Oct 18
3Rs Management And Consulting Aps
EntityCompany
Shares6,997
Max Pricekr35.00
Sellkr382,57025 Oct 18
3Rs Management And Consulting Aps
EntityCompany
Shares9,839
Max Pricekr39.30

Ownership Breakdown


Management Team

  • Tina Lawesson

    Vice President of Marketing & Communications.

    • Tenure: 0.8yrs
  • Mikael Wahlgren (54yo)

    Deputy CEO & Chief Legal Officer

    • Tenure: 2.8yrs
  • Peter Nählstedt (45yo)

    Acting VP of Sales & Director

    • Tenure: 1.8yrs
  • Axel Sjöblad (52yo)

    Chief Executive Officer

    • Tenure: 0.3yrs
  • Anna Hansson (46yo)

    Vice President of Business Development.

    • Tenure: 0.8yrs
  • Marianne Olsson (58yo)

    Vice President of Finance

    • Tenure: 2.9yrs
  • Maria Agemark (45yo)

    Vice President of Operations

    • Tenure: 1.8yrs
  • Gunilla Grundström (51yo)

    Vice President of Research & Development.

    • Tenure: 0.8yrs

Board Members

  • Carl Arne Borrebäck (71yo)

    Chairman of the Board

    • Tenure: 4.8yrs
    • Compensation: kr200.00k
  • Anki Hager (54yo)

    Director

    • Tenure: 0.4yrs
    • Compensation: kr1.77m
  • Laura Chirica (51yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: kr100.00k
  • Peter Nählstedt (45yo)

    Acting VP of Sales & Director

    • Tenure: 1.8yrs
  • Ann Gidner (53yo)

    Director

    • Tenure: 5.8yrs
    • Compensation: kr100.00k
  • Ian Kimber (69yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: kr100.00k

Company Information

SenzaGen AB's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SenzaGen AB
  • Ticker: SENZA
  • Exchange: OM
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr278.545m
  • Shares outstanding: 15.74m
  • Website: https://senzagen.com

Location

  • SenzaGen AB
  • Building 401
  • Scheelevägen 2
  • Lund
  • Skåne County
  • 223 81
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SENZAOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKSep 2017
SZGE.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDSep 2017

Biography

SenzaGen AB, together with its subsidiary, markets, sells, and performs in vitro genomic allergen rapid detection (GARD) sensitization tests for the screening of pharmaceutical candidates, and safety asses ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 21:54
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.